Dr. Bhatia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Mailstop CE2-112
Seattle, WA 98109Phone+1 206-606-7222
Summary
- Dr. Shailender Bhatia is a medical oncologist in Seattle, WA and is affiliated with University of Washington (UW), and Fred Hutchinson Cancer Center (FHCC.) He serves as the Clinical and Clinical Research Director of the Melanoma and Renal Cancer Program at FHCC. Dr Bhatia received his medical degree from All India Institute of Medical Sciences (AIIMS) and subsequently completed hematology-oncology training at UW/FHCC. He has been practicing oncology for >15 years. He specializes in skin cancers (including melanoma and Merkel cell carcinoma) and has led numerous cutting-edge clinical trials of immunotherapy in skin cancers, many of which led to FDA-approval of new agents. He has more than 100 publications, which have over 20,000 citations.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of ConnecticutResidency, Internal Medicine, 2001 - 2004
- All India Institute of Medical SciencesClass of 2000
Certifications & Licensure
- WA State Medical License 2004 - 2025
- CT State Medical License 2004 - 2005
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma Start of enrollment: 2023 Nov 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1500 citationsAdjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance
The New England Journal of Medicine. 2017-09-10 - 1375 citationsTumor and Microenvironment Evolution during Immunotherapy with Nivolumab.Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Walter J. Urba
Cell. 2017-11-02 - 38 citationsMajor pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of responseJulie E. Stein, Abha Soni, Liudmila V Danilova, Tricia R. Cottrell, Thomas F. Gajewski
Annals of Oncology. 2019-04-01
Press Mentions
- Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023
- Merck Could Keep Its Patent Edge by Shifting Keytruda Cancer Drug to a Simple ShotDecember 2nd, 2022
- Exploring Immunotherapy for the Treatment of Merkel Cell Carcinoma: Shailender Bhatia, MD, and Ciara Kelly, MBBCh, BAOJuly 6th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: